Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice -
4 hours ago
- #CDK4/6 inhibitors
- #real-world evidence
- #metastatic breast cancer
- The study compared real-world progression-free survival 2 (rwPFS2) and tumor response (rwTR) among three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with an aromatase inhibitor in HR+/HER2- metastatic breast cancer patients in US routine practice.
- Using retrospective data from 9,146 patients, the analysis found no significant differences in rwPFS2 or rwTR across pairwise comparisons of the CDK4/6 inhibitors after statistical adjustment for baseline characteristics.
- Results were consistent across subgroups and sensitivity analyses, including a subset treated from 2017 when all three inhibitors were commercially available in the US.
- The study concluded that there are no statistically significant differences in effectiveness among the three CDK4/6 inhibitors when used in first-line therapy with an aromatase inhibitor in real-world clinical settings.